A Randomized, Open-label, Active-controlled Study to Evaluate Social Functioning of Long Acting Injectable Risperidone and Oral Risperidone in the Treatment of Subjects With Schizophrenia or Schizoaffective Disorder

  • PDF icon for CSR Summary CSR Summary Not Available
  • Globe symbol for NCT Number NCT00992407
  • Notebook for Primary Citation Primary Citation Not Yet Available
  • Spreadsheet for Data Specification Data Specification Not Available

Trial Information

Generic NameRisperidoneProduct NameRISPERDAL CONSTA®Therapeutic AreaNervous SystemProduct ClassPsycholepticsPharmacological SubgroupAntipsychoticsChemical SubgroupOther AntipsychoticsCondition StudiedSchizophrenia
Sponsor Protocol NumberRISSCH4178Enrollment75Data PartnerJohnson & Johnson% Female39%Mean/Median Age (Years)34.5% WhiteN/A

Supporting Documentation

Additional Information

Please note: individual participant-level data are not available for this trial. Only the synoptic report is available.

Approved Data Requests Associated with this Trial

Disclaimer

Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.